Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24aca9ded2638ea793d05360dde7a4a0 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2513-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-415 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0619 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-062 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-079 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-00 |
filingDate |
2019-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cf5030f92e550236a69d2801c517fb9 |
publicationDate |
2020-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
TW-202024323-A |
titleOfInvention |
Cell mass containing olfactory nerve cell or its precursor cell, and method for manufacturing the same |
abstract |
Provided is a method for manufacturing a cell mass containing olfactory nerve cells or its precursor cell which comprises the following steps (1) to (3): step (1) of culturing pluripotent stem cells in suspension in the presence of a first Wnt signal transduction pathway inhibitor to form cell aggregates, step (2) of culturing the cell aggregate obtained in the step (1) in suspension in the presence of a substance acting on a BMP signal transduction pathway, and step (3) of obtaining the cell mass by suspension culture of the cell aggregate obtained in the step (2), wherein step (3) comprises at least one step selected from the group consisting of step (3a) of culturing in suspension in the presence of an FGF signaling pathway agent, step (3b) of culturing in suspension in the presence of a BMP signaling pathway inhibitor (3b), and step (3c) of culturing in the presence of an FGF signaling pathway agonist and a BMP signaling pathway inhibitor. |
priorityDate |
2018-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |